Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 30 December 2025 - 31 December 2025

JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

NEW YORK, December 30, 2025, 18:51 ET — After-hours Johnson & Johnson (JNJ) shares edged lower in after-hours trading on Tuesday after the healthcare conglomerate said it had completed its acquisition of Halda Therapeutics. The stock was down 0.3% at $206.91. The completion matters because investors are resetting portfolios into year-end with interest rates back in focus and dealmaking under…
31 December 2025
···
Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

NEW YORK, December 30, 2025, 5:08 PM ET — After-hours Eli Lilly shares were up 0.1% in after-hours trading on Tuesday at $1,079.75 after a Reuters report said it and Novo Nordisk are lowering prices of their top-selling obesity drugs in China. Reuters The pricing move matters because investors have treated Lilly’s obesity franchise as a main growth engine, helping…
30 December 2025
··
Terns Pharmaceuticals stock slides today, testing the $40 level after December share sale

Terns Pharmaceuticals stock slides today, testing the $40 level after December share sale

NEW YORK, December 30, 2025, 15:30 ET — Regular session. Shares of Terns Pharmaceuticals, Inc. fell 2.8% to $40.34 in afternoon trading on Tuesday, after swinging between $39.99 and $41.98. The pullback puts the stock back around $40, the price used in the company’s recent upsized equity offering — a level traders often watch after a big deal resets supply…
30 December 2025
····
Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

NEW YORK, December 30, 2025, 2:30 PM ET — Regular session Shares of Catalyst Pharmaceuticals, Inc. fell 3.0% to $23.33 in afternoon trading on Tuesday. The stock has traded between $23.30 and $24.10 so far in the session. The drop matters because trading can get choppy in the final days of the year, when fewer investors are active and price…
30 December 2025
····
Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib

Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib

NEW YORK, December 30, 2025, 14:40 ET — Regular session Shares of Cogent Biosciences, Inc. fell 2.7% to $36.88 on Tuesday after the biotech said it submitted a New Drug Application to the U.S. Food and Drug Administration for its drug candidate bezuclastinib in nonadvanced systemic mastocytosis. Yahoo Finance An NDA is the formal request asking the FDA to review…
30 December 2025
····
Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch

Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch

NEW YORK, December 30, 2025, 2:56 PM ET — Regular session Amgen Inc. shares were down 0.4% at $328.32 at 2:56 p.m. ET on Tuesday, after trading between $325.90 and $330.18. The modest move matters because investors are grading Amgen’s pipeline for new growth while several mature products face price pressure and biosimilar competition. Oncology and obesity remain two key…
30 December 2025
····
Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

NEW YORK, December 30, 2025, 13:47 ET — Regular session Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shares were down 3.6% at $67.09 at 1:47 p.m. ET on Tuesday, after trading between $65.94 and $69.95. The stock’s drop came as biotech weakened but the wider market held steady, a setup that can amplify moves in higher-volatility drug developers. The SPDR S&P Biotech ETF…
30 December 2025
···
Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

NEW YORK, December 30, 2025, 13:33 ET — Regular session Rhythm Pharmaceuticals shares were down 4.2% at $107.85 at 1:33 p.m. ET on Tuesday, after trading as low as $106.65. The move matters because Rhythm is a single-product rare-disease biotech whose stock has tended to swing on regulatory and clinical milestones for Imcivree, its obesity drug. Investors are watching the…
30 December 2025
···
AbbVie stock slips today as Fed minutes loom in thin year-end trade

AbbVie stock slips today as Fed minutes loom in thin year-end trade

NEW YORK, December 30, 2025, 12:55 ET — Regular session AbbVie Inc. shares fell 0.8% to $228.89 in midday trading on Tuesday. The stock ranged between $228.66 and $231.55 after opening at $230.77, with volume near 795,000 shares. The move came as Wall Street traded with little direction in holiday-thinned turnover, leaving the Dow down 0.24%, the S&P 500 off…
30 December 2025
····
Johnson & Johnson stock today: JNJ slips after $3.05B Halda cancer deal closes, Barclays lifts target

Johnson & Johnson stock today: JNJ slips after $3.05B Halda cancer deal closes, Barclays lifts target

NEW YORK, December 30, 2025, 12:44 ET — Regular session Johnson & Johnson shares edged lower on Tuesday after the company said it completed its $3.05 billion cash purchase of cancer-therapy developer Halda Therapeutics. The stock was down about 0.2% at $207.12 in midday trading. Executive vice president Jennifer Taubert called the closing a “strategic milestone” as J&J flagged about…
30 December 2025
···
Outlook Therapeutics stock jumps ahead of FDA’s Dec. 31 Lytenava decision

Outlook Therapeutics stock jumps ahead of FDA’s Dec. 31 Lytenava decision

NEW YORK, December 30, 2025, 01:25 ET — Market closed Outlook Therapeutics, Inc. shares closed Monday up 8.8% at $1.98 after trading between $1.78 and $1.98. The stock was last up about 2% at $2.02 in late after-hours trading, with about 5.7 million shares changing hands. StockAnalysis Traders are zeroed in on a Dec. 31 deadline at the U.S. Food…
30 December 2025
····
1 … 17 18 19 20 21 … 46

Stock Market Today

  • Microequities Asset Management Group (ASX:MAM) Posts 0.9% Total Shareholder Return over Three Years
    January 22, 2026, 5:47 PM EST. Microequities Asset Management Group's (ASX:MAM) share price dropped 16% over the past three years, underperforming the market's approximate 30% gain. The company's earnings per share (EPS) declined about 20% annually, yet the market maintains a degree of optimism. Including dividends, the total shareholder return (TSR) modestly improved to 0.9% for the period, highlighting the role of dividends in offsetting price losses. TSR in the last 12 months reached 9.5%, and 11% annually over five years. Investors should weigh these returns against identified investment risks flagged for MAM, making comprehensive risk assessment essential before investing.
Go toTop